A new predictive framework reprograms T cells to sustain immune memory while preserving their ability to fight cancer and infections.

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has uncovered new genetic rules that determine ...

LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

T cells sit at the center of modern immunotherapy, yet many of the rules that govern their activation, differentiation, dysfunction (e.g., exhaustion), and ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

All-RNA gene writing for T cells (RetroT): Utilizes human LINE-1 machinery to drive programmable, site-specific integration of multi-kb payloads, without DSBs, supporting a superior genomic safety ...